A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

NCT03345836 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

624

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: Matching Placebo for Upadacitinib
DRUG: Upadacitinib

Sponsor

AbbVie